Eraxis
Eraxis - General Information
Eraxis or Eraxis is an anti-fungal drug manufactured by Pfizer that gained approval by the Food and Drug Administration (FDA) in February 21, 2006; it was previously known as LY303366. There is preliminary evidence that it has a similar safety profile to caspofungin. [Wikipedia]
Pharmacology of Eraxis
Eraxis is a semi-synthetic lipopeptide synthesized from a fermentation product of Aspergillus nidulans. Eraxis is an echinocandin, a class of antifungal drugs that inhibits the synthesis of 1,3-β-D-glucan, an essential component of fungal cell walls. Eraxis is active in vitro against Candida albicans, C. glabrata, C. parapsilosis, and C. tropicalis.
Eraxis for patients
Eraxis Interactions
No clinically relevant drug-drug interactions have been observed with drugs likely to be co-administered with anidulafungin.
Eraxis Contraindications
Anidulafungin is contraindicated in persons with known hypersensitivity to anidulafungin, any component of anidulafungin, or other echinocandins.
Additional information about Eraxis
Eraxis Indication: For use in the treatment of the following fungal infections: Candidemia and other forms of Candida infections (intra-abdominal abscess, and peritonitis) and esophageal candidiasis.
Mechanism Of Action: Eraxis is a semi-synthetic echinocandin with antifungal activity. Eraxis inhibits glucan synthase, an enzyme present in fungal, but not mammalian cells. This results in inhibition of the formation of 1,3-β-D-glucan, an essential component of the fungal cell wall.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Anidulafungin
Synonyms: Not Available
Drug Category: Antibiotics, Antifungal
Drug Type: Small Molecule; Approved
Other Brand Names containing Anidulafungin: Eraxis;
Absorption: Not Available
Toxicity (Overdose): During clinical trials a single 400 mg dose of anidulafungin was inadvertently administered as a loading dose. No clinical adverse events were reported. The maximum non-lethal dose of anidulafungin in rats was 50 mg/kg, a dose which is equivalent to 10 times the recommended daily dose for esophageal candidiasis (50mg/day).
Protein Binding: 84%
Biotransformation: Hepatic metabolism of anidulafungin has not been observed. Anidulafungin is not a clinically relevant substrate, inducer, or inhibitor of cytochrome P450 (CYP450) isoenzymes. Anidulafungin undergoes slow chemical degradation at physiologic temperature and pH to a ring-opened peptide that lacks antifungal activity.
Half Life: 40-50 hours
Dosage Forms of Eraxis: Not Available
Chemical IUPAC Name: Not Available
Chemical Formula: C58H73N7O17
Anidulafungin on Wikipedia: https://en.wikipedia.org/wiki/Anidulafungin
Organisms Affected: Aspergillis, Candida and other fungi
